INTRODUCTION
============

Nephrogenic adenoma (also called nephrogenic metaplasia) was first described in 1949 as a hamartoma of the bladder -- a "tumor-like nodule of superfluous tissue retaining the basic structure of the tissue in which it was situated and differentiated from it by hyperplasia" ([@B1]). In 1950, the term 'nephrogenic adenoma' (NA) was coined in a case series of patients describing similar pathologic findings in the bladder ([@B2]). Small case series have reported NA occurring concurrently with bladder cancer ([@B3], [@B4]--[@B7]). Though TCC may be concurrent with the findings of nephrogenic adenoma, malignant transformation of nephrogenic adenoma has only been demonstrated in a few small case series ([@B8]--[@B10]). The predisposing factors for this lesion are poorly understood, though many studies will report prior trauma or inflammation to play a role in the development of NA such as recurrent urinary tract infections, chronic catheterization or administration of intravesical therapy ([@B3]--[@B5], [@B7], [@B8], [@B10]--[@B15]). Given its rarity, there are very few large series to assess these concerns and no clear guidance on its management and follow-up ([@B16]).

We examined our institution\'s experience with patients diagnosed with nephrogenic adenoma of the bladder to determine any predisposing factors for nephrogenic adenoma and also to de-termine if any patients subsequently developed a *de novo* bladder cancer.

MATERIALS AND METHODS
=====================

This study was approved by our Institutional Review Board. Utilizing our institution\'s pathology database, we compiled all patients diagnosed with NA of the bladder from 2001-2013. Only patients with an initial, *de novo* diagnosis were included. NA of the upper tract or other locations other than the bladder was not included in this retrospective review. The pathology slides and compilation of pathology reports were completed by the genitourinary pathologists at our institution.

Possible predisposing factors as well as other clinical history were reviewed. These included prior catheterizations, urologic history, recurrent infections, history of transplant, and concomitant bladder cancer. Concurrent bladder cancer diagnosis was defined as a patient with nephrogenic adenoma and bladder cancer in the same specimen. We also tracked any patients with a *de novo* diagnosis of bladder cancer subsequent to their diagnosis of NA. Recurrence of NA was defined as a patient completely treated for NA with resection that subsequently developed a new lesion.

RESULTS
=======

Sixty patients with NA of the bladder were identified. The average age at diagnosis was 61 (range 8-91). There was only one pediatric patient. The majority of the population was male (68.3%) and had a smoking history (58.3%). There were only 3 (5%) patients with a history of renal transplant and 21 (35%) patients with a history of chronic kidney disease. All but two patients had prior urologic history including prostate cancer, interstitial cystitis, bladder cancer and neurogenic bladder ([Table-1](#t1){ref-type="table"}). Fifteen (25%) patients were found to have been intermittently catheterized or have a current indwelling Foley catheter and 18 (30%) patients had a prior history of recurrent urinarytract infections defined as greater than or equal to three infections in a year. The most common presenting symptoms were lower urinary tract symptoms (35%) and hematuria (28.3%) ([Table-2](#t2){ref-type="table"}).

###### Patient Characteristics.

  Gender                                                                 
  ------------------------------------ --------------------------------- --------------
                                       Male                              68% (n=41)
                                       Female                            32% (n=19)
  Average BMI                          28.7                              
  Average age at diagnosis             61 years (range 8-91)             
  Smoking history                      58% (n=35)                        
  History of Bladder Cancer            41.7% (n=25)                      
  **Trauma/Irritative Risk Factors**                                     
                                       History of Intravesical Therapy   26.7% (n=16)
                                       History of CIC/Catheter           26.7% (n=16)
                                       History of recurrent UTI          30% (n=18)

**BMI** = body mass index; **CIC** = clean intermittent catheterization; **UTI** = urinary tract infection

###### Presenting Symptoms Prior to Cystoscopy.

  Symptoms            Number of Patients
  ------------------- --------------------
  LUTS                21 (35%)
  Hematuria           15 (25%)
  Asymptomatic        9 (15%)
  Incontinence        8 (13%)
  Dysuria             4 (7%)
  Recurrent UTI       4 (7%)
  Urinary Retention   4 (7%)
  Flank Pain          2 (3%)
  Stone               1 (2%)
  Other               1 (2%)

**LUTS** = lower urinary tract symptoms; **UTI** = urinary tract infection

The surgical specimens on which NA were diagnosed included 14 transurethral resections (TURs), 34 biopsies, and 10 cystectomies for concurrent advanced bladder. Previous bladder cancer history was present in 25 (41.7%) patients and 16 (26.7%) had undergone Bacillus Calmette-Guerin or mitomycin C instillations. Ten of the patients had NA diagnosed concurrently with their bladder cancer. Ten of the patients had NA diagnosed only on the cystectomy specimen with no prior NA diagnosis. Two other patients had cystectomies for invasive bladder cancer following their diagnosis of NA and known concurrent bladder cancer.

Of the 50 patients who had not undergone cystectomy, thirty-four patients had a follow-up cystoscopy. Recurrence was noted in 5 (14.7%) patients. Three of the patients had diffuse involvement of the bladder with NA at presentation and were likely incompletely resected while two of them had only singular small areas of NA. All were managed with biopsy and/or resection along with fulguration. In the setting of diffuse involvement of the bladder (more than 25% of the bladder surface involved) these often required multiple fulgurations for relief of symptoms and clearance of the lesions. None of these patients with recurrence had a history of bladder cancer or concurrent bladder cancer. Overall, despite the high proportion of patients with bladder cancer in this series, no patients were diagnosed with a bladder cancer after NA at an average follow-up of 10.1 months.

DISCUSSION
==========

NA is still considered a rare finding; however, reports of its occurrence have increased since its initial description in 1949 ([Table-3](#t3){ref-type="table"}). Direct cystoscopic visual findings of these lesions ([Figure-1](#f1){ref-type="fig"}) are varied across multiple studies but often can mimic other urologic conditions such as urothelial carcinoma or chronic cystitis ([@B16]). There too exists variation in subtypes of the NA pathologic findings. [Figure-2](#f2){ref-type="fig"} shows an example of a pathology slide at 200 magnification showing papillary cores that are lined by a single layer of cuboidal epithelium which contain acinar structures and dilated tubules. To our knowledge, this is the largest clinical cohort of NA of the bladder published. This study found that the most common presentation of NA is lower urinary tract symptoms and hematuria, which according to AUA Guidelines would lead to an evaluation with a cystoscopy ([@B17]). Other presentations included retention, dysuria, recurrent UTIs and some were asymptomatic. The exact etiology of nephrogenic adenoma has not been identified, but there are reports of patients with renal transplantation being at risk for developing nephrogenic adenoma ([@B3], [@B6]). Mazal et al. looked at NA in patients with kidney transplantation and found that the cells originated from the donor kidney tubular cells and not from the urothelial mucosa. It is likely that seeding from the kidney of these renal-like cells is the same etiology in non-transplant patients ([@B8]).

###### Summary of publications reviewing patients with nephrogenic adenoma of the bladder.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors                       Publication Year   Study Population         Association with Bladder Cancer            Presenting Symptoms                                          Risk Factors                                                                 Recurrence                             Conclusion
  ----------------------------- ------------------ ------------------------ ------------------------------------------ ------------------------------------------------------------ ---------------------------------------------------------------------------- -------------------------------------- -----------------------------------------------------------------------
  Kaswick et al. ([@B13])       1976               2                        No                                         Hematuria Incontinence                                       History of prior urosurgery History of UTI                                   1 recurrence                           -treatment with TUR, antibiotics\
                                                                                                                                                                                                                                                                                                        -monitor for recurrence

  Molland et al. ([@B15])       1976               3 patients               No                                         Unknown                                                      Unknown                                                                      Unknown                                Malignant transformation to adenocarcinoma in one patient

  Ford et al. ([@B4])           1985               70 (35 within bladder)   7 patients with TCC                        Incidental findings                                          History of prior urosurgery                                                  15 patients                            No malignancy in 12 year follow up

  Oliva et al. ([@B5])          1995               80 (42 within bladder)   No                                         N/A                                                          Prior urosurgery nephrolithiasis infection                                   N/A                                    NA with bland cytologic features

  Peeker et al. ([@B6])         1997               31 (24 within bladder)   7 patients with UCC                        Hematuria Urinary frequency Bladder Pain                     History of renal transplant (1) History of prior urosurgery History of UTI   7 patients                             -Trauma to urothelial mucosa may lead to NA\
                                                                                                                                                                                                                                                                                                        - TUR as method of management

  Tse et al. ([@B18])           1997               22                       6 patients with TCC                        Hematuria Urinary frequency Incidental                       History of renal transplant (7) Recurrent UTI History of prior urosurgery    6 patients                             With association to TCC, NA should be taken seriously and followed up

  Porcaro et al. ([@B12])       2001               8                        3 patients with TCC                        Hematuria Irritative voiding symptoms                        History of prior urosurgery                                                  5 patients                             -Features of NA nonspecific but TUR will diagnose & treat\
                                                                                                                                                                                                                                                                                                        -high recurrence rate requiring follow up

  Chen et al. ([@B11])          2006               8                        No                                         Hematuria Urinary frequency                                  History of urosurgery History of catheterization History of UTI              3 patients (median relapse 7 months)   -NA is a benign lesion\
                                                                                                                                                                                                                                                                                                        -recurrence is high

  Hungerhuber et al. ([@B19])   2008               1                        Progression to adenocarcinoma              Hematuria                                                    History of urosurgery                                                        Yes                                    NA may have malignant potential and warrants follow up

  Dhaliwal et al. ([@B10])      2012               1                        Progression to Clear cell adenocarcinoma   Hematuria Proteinuria                                        History of urosurgery                                                        No                                     Malignant transformation can occur with NA

  Kuzaka et al. ([@B3])         2014               3                        1 patient with TCC                         Hematuria                                                    History of recurrent UTI History of prior urosurgery                         2 patients (5 and 9 months)            -NA is a benign lesion\
                                                                                                                                                                                                                                                                                                        -Recurrence is high

  Gordetsky et al. ([@B7])      2016               31 (26 within bladder)   12 patients with UCC                       Hematuria Urinary incontinence Hydronephrosis Asymptomatic   History of renal transplant (1) History of DM (8 patients)                   1 patient                              -NA is a benign lesion
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**TCC** = transitional cell carcinoma; **N/A** = not applicable; **NA** = nephrogenic adenoma; **UCC** = urothelial cell carcinoma; **TUR** = transurethral resection; **DM** = diabetes mellitus
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![The papillary cores are lined by a single layer of cuboidal epithelium. They contain acing structures and dilated tubules.](1677-5538-ibju-44-03-0506-gf02){#f2}

Similar to the majority of other studies, we found a male predominance ([@B2], [@B5], [@B7], [@B11], [@B12]). Though this study focused on NA of the bladder, other studies have assessed other locations but all showed bladder as the most common location ([@B4], [@B5], [@B11], [@B12]). Similar to prior studies most of our patients had well-defined urologic issues prior to the diagnosis, including recurrent urinary tract infections, benign prostatic hyperplasia, interstitial cystitis or urothelial cell carcinoma ([@B3]--[@B5], [@B7], [@B8], [@B13]--[@B15]).

The vast majority of studies have supported that NA is a benign lesion ([@B3]--[@B5], [@B7], [@B11]); NA is not associated with deep invasion, mitotic activity, neoplastic-type atypia, or de-differentiation. NA generally grows slowly, and there has been no convincing evidence of any malignant transformation of NA ([@B1], [@B2], [@B4], [@B11], [@B12]).

Though multiple studies demonstrate the benign pathologic findings along with clinical absence of progression to malignancy ([@B2], [@B4], [@B5], [@B11], [@B12], [@B18]), a single study reported a case of nephrogenic adenoma that ultimately developed into adenocarcinoma 2 years later with later findings of metastatic adenocarcinoma. They refer to studies in which the association between nephrogenic metaplasia and clear cell adenocarcinoma was seen in the Pax 8 staining seen in both but not with urothelium, prostatic adenocarcinoma or urothelial carcinoma. This case study, however, may instead represent what has been described as a clear cell adenocarcinoma with diffuse areas mimicking NA ([@B8]). Other studies have also reported the possible relation between nephrogenic adenoma and mesonephric adenocarcinoma warranting aggressive follow-up and management, but these studies are rather old ([@B9], [@B19]). Overall, the vast majority of the recent literature, including our study, supports that NA is a benign reactive lesion with no associated increased risk of the development of bladder cancer.

There are no guidelines at present on the management and follow-up of nephrogenic adenoma. Recurrence rates have differed across studies. Our study showed recurrence in five patients and Gordetsky\'s recent study found one in 31 patients with recurrence. Other studies had varying numbers of recurrence, but recommendations were made to have long term follow-up as recurrences were common ([@B5]--[@B8], [@B13], [@B14], [@B20]). Given the symptomatic nature of this lesion and its tendency to recur, it would be prudent to follow patients with a cystoscopy and treat any of these recurrences. The exact timeline of cystoscopic follow-up is unknown, but based on the studies reviewed, patients were already on a surveillance schedule based on their history of bladder cancer and/or they presented with recurrent symptoms of hematuria or lower urinary tract symptoms which would prompt a re-evaluation. Follow-up noted in each of the studies varied largely from 2-24 months with reported average recurrence occurring within the first year ([@B3], [@B13]). We would recommend standard follow-up for bladder cancer patients. A possible plan for patients with nephrogenic adenoma alone may be a follow-up cystoscopy within 6-12 months from the initial diagnosis and then with symptom recurrence. Larger studies with longer follow-up will best answer this question.

Based on our review, this is the largest study of a cohort of 60 patients with an average 10.1 month follow up of patients with nephrogenic adenoma of the bladder. However, we do re-cognize there are limitations to the conclusions from this study. This is a retrospective chart re-view of patients identified by our pathology database. Our average follow-up was only 10.1 months, and only 68% of the population with intact bladders underwent follow-up cystoscopy. There is also likely a selection bias favoring more severe disease involvement as likely only symptomatic patients and/or patients with a history of bladder cancer would undergo cystoscopy and there are likely asymptomatic patients in the community who have small non-symptomatic lesions that we do not capture.

CONCLUSIONS
===========

In conclusion, patients with nephrogenic adenoma represent a heterogeneous population with varying presentations that cover the wide span of urologic subspecialties. NA has not been shown to lead to malignant progression in this study and in the majority of the literature. There is a predilection for patients that are male with priorurologic conditions; the most common presenting symptoms being lower urinary tract symptoms or hematuria. Recurrence does occur, but was noted to be relatively uncommon in this study. As for management, patients who are under surveillance for bladder cancer should continue the surveillance schedule with biopsy/resection of lesions that may appear suspicious as per usual regimen. Patients with a diagnosis of only nephrogenic adenoma should likely undergo repeat cystoscopy to confirm eradication of the lesions after resection, but given the limited data a follow-up regimen is difficult to establish.
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